Denali Therapeutics Inc. (DNLI) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Denali Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Denali Therapeutics Inc. (DNLI) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $3.1B. It trades at $19.29, up 0.36% today. Its overall quality score is 32 out of 100, ranked against the whole US market. 11 analysts' average target of $36.11 implies +87.2% from today's price. Kronos AI's 30-day forecast is +6.9% (7 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $36.11 |
| Low – high | $29.00 – $42.00 |
| Analysts | 11 |
| Upside to average | +87.2% |
Kronos AI 30-day forecast
| Expected close | $20.55 (+6.9%) |
| Likely range | +0.7% … +9.9% |
| As of | 2026-10-27 |
Quality scores
| Profitability | 7 |
| Solvency | 54 |
| Growth | 36 |
| Overall | 32 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Halal Health Care stocks · Zakat calculator · Purification calculator